Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis.

about

Protection of the Human Gut Microbiome From Antibiotics.

P2860

Q49548833-FF1D68EC-0ADC-48B9-A52B-C366A30E9156

P2860

Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis.

Item

http://www.wikidata.org/entity/Q40121761

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Protection of hamsters from mo ...... Clostridium difficile colitis.

@en

type

Item

label

Protection of hamsters from mo ...... Clostridium difficile colitis.

@en

prefLabel

Protection of hamsters from mo ...... Clostridium difficile colitis.

@en

P1476

Protection of hamsters from mo ...... Clostridium difficile colitis.

@en

P2093

Antoine Andremont

http://www.w3.org/2001/XMLSchema#string

Christine Miossec

http://www.w3.org/2001/XMLSchema#string

France Mentré

http://www.w3.org/2001/XMLSchema#string

Jean de Gunzburg

http://www.w3.org/2001/XMLSchema#string

Mark Pulse

http://www.w3.org/2001/XMLSchema#string

Nathalie Saint-Lu

http://www.w3.org/2001/XMLSchema#string

Sakina Sayah-Jeanne

http://www.w3.org/2001/XMLSchema#string

Thu Thuy Nguyen

http://www.w3.org/2001/XMLSchema#string

William Weiss

http://www.w3.org/2001/XMLSchema#string

P2860

Interactions Between the Gastrointestinal Microbiome and Clostridium difficile

Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation.

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Burden of Clostridium difficile infection in the United States.

Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea.

Orally administered targeted recombinant Beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance.

Penetration of moxifloxacin into the human aqueous humour after oral administration.

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.

P31

scholarly article

P356

10.1128/AAC.00543-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Charles Burdet

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28739791

http://www.w3.org/2001/XMLSchema#string

P818

1709.07193

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

Aka

P932

5610506

http://www.w3.org/2001/XMLSchema#string

Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis.

about

P2860

P2860

Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P818

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P818

P921

P932